Singapore markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7350+0.0050 (+0.18%)
As of 10:34AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.7300
Open2.7400
Bid2.7100 x 300
Ask2.7600 x 300
Day's range2.7150 - 2.7550
52-week range1.6900 - 3.2900
Volume146,106
Avg. volume1,410,221
Market cap492.779M
Beta (5Y monthly)2.09
PE ratio (TTM)N/A
EPS (TTM)-0.4400
Earnings date02 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.40
  • Zacks

    Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

    Here is how Arbutus Biopharma (ABUS) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year.

  • GlobeNewswire

    Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

    WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for Thursday, May 2, 2024. The schedule for the press release and conference call/webcast are as follows: •Q1 2024 Press Relea

  • GlobeNewswire

    Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

    WARMINSTER, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences (Plaintiffs) against Mod